# Cannabis Significantly Reduces Tourette Syndrome Tic Severity > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-significantly-reduces-tourette-syndrome-tic-severity/ > **Published:** 2026-06-26T17:21:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:21:12-04:00 > **Clinical Summary:** Systematic review shows cannabis significantly reduces Tourette syndrome tic severity. Evidence, clinical use, and patient selection guidance. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyResearchTHCCBDMental HealthSafetyPolicy Why This Matters Clinicians treating patients with Tourette syndrome now have emerging evidence that cannabis may offer a therapeutic option for tic reduction when conventional treatments fail or cause intolerable [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/). This finding is particularly relevant given that current pharmacological options (antipsychotics, alpha-2 agonists) have limited efficacy in some patients and significant adverse effect profiles. Understanding cannabis’s potential role allows clinicians to have informed discussions with patients about evidence-based alternatives and may expand treatment options for this difficult-to-manage neurological condition. Clinical Summary A [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) and meta-analysis examining [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in Tourette syndrome found significant reductions in tic severity across included studies, suggesting potential therapeutic benefit for patients with this movement disorder. The evidence base, while limited, indicates that cannabinoids may modulate the neural circuits underlying tic generation, offering an alternative option for patients who are inadequately controlled on or intolerant of conventional pharmacotherapies such as antipsychotics and alpha-2 agonists. However, the heterogeneity of study designs, dosing regimens, cannabinoid compositions, and outcome measures highlights the need for well-controlled prospective trials to establish optimal dosing and to clarify which patient populations benefit most. Clinicians should be aware that while these findings are encouraging, cannabis remains a Schedule I controlled substance in many jurisdictions, complicating legal prescribing and insurance coverage; regulatory status varies considerably by region. Given the severity of Tourette syndrome and its impact on [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/), physicians may consider discussing cannabis as a potential adjunctive or alternative option with appropriate patients, while emphasizing the need for further high-quality evidence and remaining vigilant for adverse effects and drug interactions. Clinicians should engage in shared decision-making with patients about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) for Tourette syndrome and document the discussion, recognizing that current evidence supports further investigation but does not yet establish it as a standard first- or second-line therapy. Dr. Caplan’s Take “The early signals here are worth watching, and I’ve certainly observed symptom improvement in some of my own patients with Tourette syndrome, but we need to be clear that the current evidence base—even with meta-analyses—still relies heavily on small studies and patient reports rather than the large, well-controlled randomized trials that would give us real clinical confidence in dosing and long-term safety.” Clinical Perspective 🧠 While emerging evidence suggests cannabinoids may reduce tic severity in Tourette syndrome, clinicians should interpret these findings cautiously given the typically small sample sizes and heterogeneous methodologies in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), along with the lack of head-to-head comparisons with established pharmacotherapies like fluphenazine or habit reversal training. The endocannabinoid system’s role in motor control is biologically plausible, but most studies lack long-term safety data, standardized dosing protocols, and rigorous assessment of potential adverse effects on cognition or motivation in this often young patient population. Additionally, variable cannabinoid concentrations, legal status in different jurisdictions, and limited access to pharmaceutical-grade products create implementation barriers that complicate clinical recommendation. For patients with Tourette syndrome inadequately controlled on conventional agents or unable to tolerate them, discussing cannabis as a potential adjunctive option may be reasonable within appropriate regulatory 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Significantly%20Reduces%20Tourette%20Syndrome%20Tic%20Severity%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67223)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67223)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Significantly%20Reduces%20Tourette%20Syndrome%20Tic%20Severity%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67223)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://norml.org/news/2026/06/25/scientific-review-cannabis-based-interventions-significantly-reduce-tic-severity-in-patients-with-tourette-syndrome/?amp](https://norml.org/news/2026/06/25/scientific-review-cannabis-based-interventions-significantly-reduce-tic-severity-in-patients-with-tourette-syndrome/?amp) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).